NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma

被引：4
|
作者：
Griffiths, Christian [1 ]
Hay, Nicola [1 ]
Sutcliffe, Frances [1 ]
Stevens, Andrew [1 ]
机构：
[1] Natl Inst Hlth & Clin Excellence, Manchester, Lancs, England
来源：
LANCET ONCOLOGY | 2011年 / 12卷 / 03期
关键词：
INTERFERON ALPHA-2A; RANDOMIZED-TRIAL; MEDROXYPROGESTERONE; VINBLASTINE;
D O I：
10.1016/S1470-2045(11)70042-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：221 / 222
页数：2
相关论文
共 50 条
  • [41] Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
    Paolo Grassi
    Elena Verzoni
    Raffaele Ratta
    Luca Porcu
    Michele Prisciandaro
    Alessia Mennitto
    Giuseppina Calareso
    Filippo de Braud
    Giuseppe Procopio
    Drugs in R&D, 2017, 17 : 461 - 467
  • [42] Pazopanib or sunitinib for metastatic renal-cell carcinoma?
    Bennet, Neil
    LANCET ONCOLOGY, 2013, 14 (11): : E442 - E442
  • [43] Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?
    Fuca, G.
    Verzoni, E.
    Ratta, R.
    Luca, P.
    Martinetti, A.
    Mennitto, A.
    Grassi, P.
    Procopio, G.
    ANNALS OF ONCOLOGY, 2017, 28
  • [44] Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma?
    Grassi, Paolo
    Procopio, Giuseppe
    Ratta, Raffaele
    Porcu, Luca
    Martinetti, Antonia
    Mennitto, Alessia
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [45] Renal cell carcinoma treatment after first-line combinations
    Porta, Camillo
    Schmidinger, Manuela
    LANCET ONCOLOGY, 2019, 20 (10): : 1332 - 1334
  • [46] Optimising first-line treatment for metastatic renal cell carcinoma
    de Velasco, Guillermo
    LANCET, 2020, 395 (10219): : E7 - E7
  • [47] Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
    Grassi, Paolo
    Verzoni, Elena
    Ratta, Raffaele
    Porcu, Luca
    Prisciandaro, Michele
    Mennitto, Alessia
    Calareso, Giuseppina
    de Braud, Filippo
    Procopio, Giuseppe
    DRUGS IN R&D, 2017, 17 (03) : 461 - 467
  • [48] Study of the effectiveness of first-line treatment in renal cell carcinoma
    Sastre-Heres, Alejandro J.
    Alaguero Calero, Miguel
    Ruiz-Sanchez, Daniel
    Iglesias Garcia, Maria Teresa
    Calleja Hernandez, Miguel Angel
    Martinez Martinez, Fernando
    Pena-Diaz, Jaime
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (06) : 1167 - 1171
  • [49] NICE guidance on bortezomib and thalidomide for first-line treatment of multiple myeloma
    Doss, Sally
    Hay, Nicola
    Sutcliffe, Frances
    LANCET ONCOLOGY, 2011, 12 (09): : 837 - 838
  • [50] First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
    Serzan, Michael T.
    Xu, Wenxin
    Berg, Stephanie A.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (05) : 951 - 964
12345